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Abstract 
Objectives 
Outcome of aortic valve replacement may be influenced by the choice of 
bioprosthesis. Pericardial heart valves are described to have a favorable hemodynamic 
profile compared to porcine valves, although the clinical notability of this finding is 
still controversially debated. Herein we compared the long-term results of two 
commonly implanted bioprothesis at a single center. 
 
Methods 
All consecutive patients undergoing isolated aortic valve replacement with either a 
Carpentier-Edwards Magna or a Medtronic Mosaic porcine prosthesis between 1997 
and 2008 were analyzed regarding preoperative characteristics, short- and long-term 
survival, valve related complications and echocardiographic findings.  
 
Results 
The Medtronic Mosaic was implanted in 290 patients and the Carpentier-Edwards 
Magna in 295 patients. The sizes of implanted valves were 22.5±1.6 mm for the 
Mosaic and 21.8±1.8 mm for the Magna (p<0.001). Long term survival rate was 73% 
and 55% after 5 and 10 years for the Medtronic Mosaic, which was comparable to the 
Carpentier-Edwards Magna (76% and 59%; p=0.688). Further, overall survival was 
comparable to an age and sex matched Austrian general population for both groups. 
The postoperative mean transvalvular gradient was significantly increased in the 
Mosaic group (23±8 mmHg versus 16±6 mmHg; p<0.001). Severe prosthesis patient 
mismatch was present in five Mosaic patients.  
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Conclusion 
Both types of aortic bioprostheses offer excellent results. Despite relevant differences 
in gradients, survival was comparable to the expected normal survival for both 
bioprostheses. Patients with a porcine heart valve had a higher prevalence of 
prosthesis patient mismatch. 
 
Keywords 
Aortic valve replacement, biologic heart valves, bioprosthesis, Survival analysis 
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Introduction 
Aortic valve replacement is among the most commonly performed procedures in 
cardiac surgery. The optimal prosthesis for aortic valve replacement has not yet been 
developed. Bioprostheses do not require a lifelong anticoagulation as opposed to 
mechanical prostheses and offer a satisfactory hemodynamic profile. However, the 
risk of structural valve degeneration has to be considered.  
The number of biologic heart valve implantations significantly increased over the last 
decades. This is not only due to an increasingly older patient cohort, where biologic 
prostheses are favoured[1, 2]. The higher durability enabled by improved 
anticalcification treatment and other optimizations of valve design led to a higher 
implantation rate in a younger patient population. The two most commonly implanted 
biologic prostheses are either stent-mounted native porcine aortic heart valves or 
bovine pericardial valves[3]. Both prostheses have proven clinical outcome over 
time[4, 5]. They have undergone modifications in design during the past decades to 
optimize hemodynamic performance and prolong durability. 
Pericardial prostheses are credited to have a favorable hemodynamic profile 
compared to porcine valves[6, 7]. However, the impact of improved postoperative 
transvalvular gradients on outcome is still a matter of debate. Furthermore, high 
transvalvular gradients in porcine heart valves seems to be at least partly caused by an 
echocardiographic phenomenon[8].  
The aim of the current study was to compare two commonly implanted bioprotheses 
at a single center in a real-world setting. The Medtronic Mosaic porcine biologic 
aortic heart valve and the Carpentier-Edwards Magna pericardial aortic bioprosthesis 
were analysed regarding survival, reoperation rate, valve related complications and 
echocardiographic data.
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Materials and Methods 
Study Population 
Data of all consecutive patients undergoing isolated aortic valve replacement with 
either a Carpentier-Edwards Magna (Edwards Lifesciences, Irvine, CA, USA) or a 
Medtronic Mosaic porcine prosthesis (Medtronic, St Paul, MN, USA) between 1997 
and 2008 at a university hospital were prospectively collected and analyzed. The 
surgeon made the decision regarding the type of valve prosthesis independent of this 
analysis. The Medtronic Mosaic was implanted since 1997 and the Carpentier-
Edwards Magna was implanted since 2002. All patients with concomitant surgical 
procedures except of root and/or annular enlargement were excluded from this 
analysis. All patients without contraindications received phenprocoumon for three 
months after surgery. Patients were followed by general practitioners and 
cardiologists without a stringent study protocol. 
 
Data management  
The internal review board approved this project (EK 955/2011). Informed patient 
consent was waived. Patients’ characteristics and risk factors were documented 
prospectively in the electronic documentation system of our institution. Risk scores 
(linear and logistic EuroSCORE) were calculated and stored. Follow up was 
performed in accordance with the current guidelines for reporting mortality and 
morbidity after cardiac valve interventions[9]. All postoperative hospitalizations and 
outpatient visits in public hospitals of the same city were assessed. In addition, every 
patient was contacted by telephone to complete follow – up. Our databank was closed 
with March 2013. 
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Mortality. Early mortality was defined as all cause mortality during the first 30 days. 
In addition to our follow – up, overall mortality was yearly crosschecked with the 
countrywide database maintained by the national statistical institute (Statistics 
Austria, Vienna, Austria). All deaths in Austria are registered in the database with the 
full name, the date of birth and the date of death. Every Austrian citizen who was 
operated at our department and died thereafter in Austria could be identified. 
Therefore, follow-up for survival is considered as complete except of foreign patients 
or patients who left the country.  
 
Morbidity. Nine percent of patients were lost to follow-up for valve related 
complications after the early postoperative period, 10% in the Edwards Magna group 
and 8% in the Medtronic Mosaic group with no significant difference between valve 
types (p=0.346).  
 
Echocardiography. At least one echocardiographic follow up in the echo lab of our 
institution could be performed in 41% of this population. We calculated the projected 
effective orifice area index (EOAI) according to the implanted valve size using 
previously published effective orifice area (EOA) measures and the actual body 
surface area[7].  
 
Statistical Analysis 
Descriptive statistical methods were applied to depict the study population regarding 
preoperative risk factors. A χ2 test was performed to analyze the frequencies of binary 
outcomes between treatment groups. Continuous variables were presented as mean 
and standard deviations and compared by the T-test. Further, analysis of variance was 
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used to assess differences in outcome parameters between valve types. The Kaplan-
Meier method with a Log-Rank test was performed to compare survival and the 
number of valve-related events between groups. Further, we calculated the average 
annual event rates by dividing the observed number of events by the number of 
follow-up years. Cumulative survival of an age and sex-matched Austrian standard 
population was computed by the life table method, based on age-sex-specific 
mortality data of the year 2005 published online by the Austrian Federal Statistical 
Agency (‘Statistics Austria’). Cumulative survival and 95% confidence intervals for 
the study population were computed using the product-limit (Kaplan-Meier) method 
and compared to the standard population. For further survival analysis, a Cox 
regression was performed for the variables ‘logistic EuroSCORE’ and ‘calculated 
PPM’. The two-sided significance level was set to 5%. The R package (R Foundation 
for Statistical Computing, Vienna, Austria) and IBM SPSS Statistics 20 (IBM, 
Armonk, New York, USA) were used for statistical analysis.  
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Results 
The Medtronic Mosaic was implanted in 290 patients (49.6%) and the Carpentier-
Edwards Magna in 295 patients (50.4%). Basic demographic data and risk scores 
were comparable between groups except for a minor difference in body weight (Table 
1). Subjects receiving the Carpentier-Edwards Magna showed a trend towards a lower 
mean transvalvular gradient prior to implantation (64±24 mmHg versus 59±24 
mmHg; p=0.094). The mean implanted valve size was 22.5±1.6 mm for the 
Medtronic Mosaic, which was significantly larger than the Carpentier-Edwards 
Magna size (21.8±1.8 mm; p<0.001, Figure 1A). Procedural characteristics including 
cross clamp time and intraoperative risk factors were comparable (Table 1).  
 
Early mortality between 1997 and 2008 was significantly higher in the Mosaic group 
(7.6% versus 2.7%; p=0.008). However, analysis of the subgroup of patients receiving 
the Medtronic Mosaic valve in the same time period as the Carpentier-Edwards 
Magna was implanted (2003 to 2008), overall early mortality was 2.9% and did not 
differ between groups (Table 1). Long term survival rate was 73% and 55% after 5 
and 10 years for the Medtronic Mosaic, which was comparable to the Carpentier-
Edwards Magna (76% and 59%;p=0.688). The overall survival (including 
perioperative mortality) was comparable to the age and sex matched survival of the 
Austrian population for both groups (Figure 2).  
 
The observed valve related complications were similar in both groups except of a 
borderline significantly increased annualized rate of peripheral emboli in the 
Carpentier-Edwards Magna group (0.7% versus 0.3%; p=0.051; Table 2). 
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The postoperative mean transvalvular gradient (4±3 months after surgery) was 
significantly higher in the Mosaic group (23±8 mmHg versus 16±6 mmHg; p<0.001; 
Figure 1B). The calculated percentage of moderate (EOAI <= 0.85cm2/m2 and > 
0.65cm2/m2) and severe prosthesis patient mismatch (EOAI <= 0.65cm2/m2) was 
significantly worse for the Medtronic Mosaic prosthesis (moderate: 49% versus 19%; 
severe 2% versus 0%; p<0.001). Severe patient-prostheses mismatch showed a trend 
towards decreased survival in a Cox-regression analysis including the preoperative 
logistic EuroSCORE (p=0.062).  
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Discussion 
Herein we present a single-center, direct, non-randomized comparison of two 
bioprostheses currently implanted in the majority of surgical aortic valve 
replacements in an elderly patient cohort[3]. In contrast to other recent publications, 
we evaluated a very distinct patient group, which was limited to isolated aortic valve 
replacements[10]. Thereby, we avoided possible confounding factors such as 
concomitant coronary artery bypass grafting or other surgical procedures. This 
resulted in a higher survival rate compared to the publication by Said et al[10]. 
However, overall survival was equal in both groups of our study. Moreover, it was 
also comparable to the age and sex matched Austrian population (Figure 2).  
The valve related complication rate was low and did only show a minor trend for 
increased peripheral emboli in the Carpentier-Edwards Magna group. Our data are 
comparable with previous publications reporting favorable survival with these valves 
in an elderly population[4, 5, 11]. Differences in early mortality between the two 
cohorts are probably related to the fact that the Medtronic Mosaic valve was 
introduced five years earlier at our department. This is confirmed by the sub-analysis 
of patients who were operated in the same time period (2003 to 2008), which showed 
similar early mortality in both valve types. 
 
The central question, which is always addressed in the literature regarding porcine 
heart valves, is the presence, cause and effect of high transvalvular gradients[7]. As 
expected, transvalvular gradients were also increased in our postoperative 
echocardiographic follow up of the Medtronic Mosaic valve. However, long-term 
survival was not affected by gradients and did not differ between groups. A potential 
explanation may be that the observed differences in gradients as such do not affect 
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long-term outcome in this elderly patient cohort. Otherwise, the observed higher 
gradients measured in the Mosaic valve could also be caused by an echocardiographic 
phenomenon[8]. The concept of this phenomenon, called pressure recovery, was 
previously published and advocates that the majority of the observed gradient in the 
Medtronic Mosaic group is again transferred to aortic pressure after the aortic 
prosthesis due to the laminar flow pattern[12].  
Another aspect has to be addressed in the discussion regarding postoperative 
transvalvular gradients. Previous publications highlighted the variable labeling of 
valve sizes and also reported a difference in the inner diameter of size-matched 
prostheses up to 2 mm[13, 14]. Therefore, studies comparing different aortic valve 
prosthesis according to the labeled implanted valve size have to be interpreted with 
caution. Our department introduced the Medtronic Mosaic early and previously 
published a randomized analysis comparing implanted valve sizes in relation to the 
real annular diameter measured with a hegar dilator[15]. The implanted Carpentier-
Edwards Magna labeled sizes were smaller compared to the Medtronic Mosaic valve 
for a standardized annular measurement. This was observed again in the current 
analysis. Not one 19mm Medtronic Mosaic valve was implanted in this patient 
population and the average diameter according to the labeled size was 0.7 mm higher 
in the Medtronic Mosaic group (Figure 1A).  
The size of the implanted prosthesis is major determinant for prosthesis patient 
mismatch[16]. A severe mismatch below 0.65cm2/m2 has been identified as a 
potential risk factor for long-term mortality[17]. Severe prosthesis patient mismatch 
may induce turbulent flow in the ascending aorta, which would theoretically diminish 
the pressure recovery effect. Our data are in line with the current perception regarding 
the impact of severe prosthesis patient mismatch on long-term survival. Five patients 
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with severe prosthesis patient mismatch were observed during the study period, all in 
the Medtronic Mosaic group. These five patients did present with a trend towards 
increased mortality. However, no difference could be detected in the moderate 
prostheses patient mismatch group as previously described[17].  
 
Limitations 
The current study is retrospective in nature. Although follow-up for survival was 
complete due to the crosscheck with the statistical institute, follow-up for valve 
related adverse events was based solely on a database research and telephone follow-
up. Restoration of normal life expectancy in elderly patients should not be 
extrapolated to younger age groups, as death from competing causes obscure valve 
related mortality. Furthermore, elderly patients accepted for cardiac surgery at a given 
age may be in a better general health condition compared to the general population.  
Only routine echocardiographic studies without a distinct time schedule were 
available. Therefore, the projected rather than the measured effective orifice area 
index was used for prosthesis patient mismatch grading. Due to the later introduction 
of the Carpentier-Edwards Magna, follow-up time periods differ between the two 
groups.  
 
In conclusion, both types of aortic bioprostheses offer excellent long-term results as 
documented by comparison with the Austrian standard population. Differences in 
transvalvular gradients had no impact on long-term survival, as long as severe 
prosthesis patient mismatch was avoided. 
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Tables 
Table 1: Preoperative patient characteristics, procedural specifications and follow up.  
Factor Porcine Pericardial P-value 
Age (years) 74±8 73±9 0.261 
Sex (f/m) 55%/45% 54%/46% 0.756 
Height (cm) 167±9 166±12 0.241 
Weight (kg) 75±14 78±18 0.037 
Body surface area (m2) 1.88±0.21 1.91±0.23 0.182 
NYHA II 34% 31% 0.813 
NYHA III-IV 61% 63% 0.813 
Linear EuroSCORE 8±3 7±3 0.111 
Logistic EuroSCORE 11±11 10±10 0.302 
EF > 50% (%) 72% 75% 0.686 
Heart rate (bpm) 73±15 72±13 0.375 
Systolic blood pressure (mmHg) 131±24 131±22 0.963 
Diastolic blood pressure (mmHg) 73±35 71±16 0.440 
FVC (l) 2.7±0.9 2.7±0.8 0.815 
FEVI (%) 88.6±21.8 87.7±23.6 0.709 
Hemoglobin (g/dl) 12.8±1.6 13.0±1.8 0.209 
Platelets (G/l) 223±72 227±69 0.494 
Creatinine (mg/dl) 1.2±0.7 1.2±0.7 0.692 
Mean preoperative gradient (mmHg) 64±24 59±24 0.094 
Duration of anesthesia (min) 277±66 275±64 0.693 
Cross clamp time (min) 59±20 57±14 0.164 
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Red blood cell units (packs) 2.7±1.7 2.8±2.2 0.598 
Valve Size (mm) 22.5±1.6 21.8±1.8 <0.001 
Revision for bleeding 6.2% 7.1% 0.658 
Early mortality (1997 – 2008) % 7.6 2.7 0.008 
Early mortality (2003 – 2008) % 3.1 2.7 0.832 
Follow Up (months) 73±44 61±27 <0.001 
 
Caption: Porcine: Medtronic Mosaic; Pericardial: Carpentier-Edwards Magna; 
Continuous data are presented as the mean ± standard deviation; categorial data as 
percentage; bpm: beats per minute. 
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Table 2: Valve related long-term outcome regarding adverse events (%/year). 
Factor Porcine Pericardial P-value 
Structural valve deterioration (reoperation) 0.3% 0.1% 0.996 
Nonstructural dysfunction (reoperation) 0.3% 0.3% 0.829 
Embolism    
     Stroke 1.8% 2.2% 0.682 
     TIA 0.6% 0.7% 0.779 
     Emboli 0.3% 0.7% 0.051 
Myocardial infarction 0.3% 0.2% 0.845 
Valve thrombosis 0.2% 0.2% 0.775 
Bleeding event 0% 0.1% 0.315 
Endocarditis 0.5% 1.0% 0.309 
Endocarditis (reoperation) 0.1% 0.3% 0.987 
 
Caption: Porcine: Medtronic Mosaic; Pericardial: Carpentier-Edwards Magna; 
Continuous data are presented as the mean ± standard deviation; categorial data as 
percentage; valve related complications are presented as annualized rates, p-values are 
retrieved from the Kaplan-Meier Log-Rank analyses. 
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Figure legends 
 
Figure 1: Implanted valve sizes and postoperative transvalvular gradients 
Caption: A) Valve sizes according to manufacturers labeling (p<0.001); B) An 
interpolation line for each group was drawn with a LOESS function. 
 
Figure 2: Cumulative survival compared the age and sex matched population 
Caption: The age and sex matched standard population represents the expected overall 
Austrian survival for the year 2005.   
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